US4791101A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Synergistic mixtures of interferons and tumor necrosis factor
Assignee: Boehringer Ingelheim GmbH
•
Filing: 1985-06-20
•
Granted: 1988-12-13
•
Expires: 2005-06-20
Abstract
Abstract Ternary compositions of an interferon of the alpha and/or beta type with an interferon of the gamma type and tumor necrosis factor having a surprising and unexpected synergistic anti-proliferative effect on neoplastic cells when compared to the activity of the individual components of this invention, said compositions being useful in the treatment of neoplasia in animals including humans.
Inventors
- 👤 Gunther Adolf
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 22:13
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/19; A61K38/21; Y; Y02; Y02A; Y02A50/00; Y02A50/30
Claims Analysis
Total Claims: 31
Claim 1
Independent Claim
36 words
A composition having a synergistic anti-proliferative effect on neoplastic animal cells, comprising a synergistically effective amount of (a) highly purified tumor necrosis factor; (b) highly purified type I interferon; and (c) highly purified type II interferon.
Claim 2
Dependent Claim
36 words
A composition having a synergistic anti-proliferative effect on neoplastic animal cells, comprising a synergistically effective amount of (a) highly purified tumor necrosis factor; (b) highly purified type I interferon; and (c) highly purified type II interferon.
Claim 3
Dependent Claim
53 words
A composition having a synergistic anti-proliferative effect on neoplastic animal cells selected from the group consisting of anal, breast, cervical, colorectal, head, lung, melanoma, and neck cancer cells, comprising a synergistically effective amount of (a) highly purified tumor necrosis factor; (b) highly purified type I inerferon; and (c) highly purified type II interferon.
Claim 4
Dependent Claim
53 words
A composition having a synergistic anti-proliferative effect on neoplastic animal cells selected from the group consisting of anal, breast, cervical, colorectal, head, lung, melanoma, and neck cancer cells, comprising a synergistically effective amount of (a) highly purified tumor necrosis factor; (b) highly purified type I inerferon; and (c) highly purified type II interferon.
Claim 5
Dependent Claim
30 words
The composition of claim 1 or 2, wherein said tumor necrosis factor, said type I interferon and said type II interferon each is greater than or equal to 90% pure.
Claim 6
Dependent Claim
14 words
The composition of claim 3, wherein said tumor necrosis factor is of mammalian origin.
Claim 7
Dependent Claim
15 words
The composition of claim 4, wherein said tumor necrosis factor is human tumor necrosis factor.
Claim 8
Dependent Claim
17 words
The composition of claim 3, said tumor necrosis factor being greater than or equal to 95% pure.
Claim 9
Dependent Claim
17 words
The composition of claim 6, said tumor necrosis factor being greater than or equal to 98% pure.
Claim 10
Dependent Claim
21 words
The composition of claim 3, wherein said type I interferon is alpha or beta or subtypes thereof, or a mixture thereof.
Claim 11
Dependent Claim
14 words
The composition of claim 8, wherein said type I interferon is of mammalian origin.
Claim 12
Dependent Claim
15 words
The composition of claim 9, wherein said type I interferon is human type I interferon.
Claim 13
Dependent Claim
13 words
The composition of claim 10, wherein said type I interferon is human interferon-alpha-2-arg.
Claim 14
Dependent Claim
17 words
The composition of claim 7, said type I interferon being greater than or equal to 95% pure.
Claim 15
Dependent Claim
17 words
The composition of claim 12, said type I interferon being greater than or equal to 98% pure.
Claim 16
Dependent Claim
16 words
The composition of claim 3, wherein said type II interferon is gamma or a subtype thereof.
Claim 17
Dependent Claim
14 words
The composition of claim 14, wherein said type II interferon is of mammalian origin.
Claim 18
Dependent Claim
14 words
The composition of claim 15, wherein said type II interferon is human interferon gamma.
Claim 19
Dependent Claim
17 words
The composition of claim 14, said type II interferon being greater than or equal to 95% pure.
Claim 20
Dependent Claim
14 words
The composition of claim 17, said type II inteferon being greater than 98% pure.
Claim 21
Dependent Claim
13 words
The composition of claim 3, further comprising a pharmaceutically acceptable carrier or carriers.
Claim 22
Dependent Claim
16 words
The composition of claim 3, wherein said type I interferon is produced by recombinant DNA methods.
Claim 23
Dependent Claim
16 words
The composition of claim 3, wherein said type II interferon is produced by recombinant DNA methods.
Claim 24
Dependent Claim
16 words
The composition of claim 3, wherein said tumor necrosis factor is produced by recombinant DNA methods.
Claim 25
Independent Claim
48 words
A method for the treatment of neoplastic disease in animals, comprising administering to an animal suffering from or suspected or suffering from said disease a synergistically effective amount of (a) highly purified tumor necrosis factor; (b) highly purified type I interferon; and (c) highly purified type II interferon.
Claim 26
Independent Claim
48 words
A method for the treatment of neoplastic disease in animals, comprising administering to an animal suffering from or suspected or suffering from said disease a synergistically effective amount of (a) highly purified tumor necrosis factor; (b) highly purified type I interferon; and (c) highly purified type II interferon.
Claim 27
Independent Claim
62 words
A method for the treatment of neoplastic disease selected from the group consisting of anal, breast, cervical, colorectal, head, lung, melanoma, and neck cancer, comprising administering to an animal suffering from or suspected of suffering from said disease a synergistically effective amount of (a) highly purified tumor necrosis factor; (b) highly purified type I interferon; and (c) highly purified type II interferon.
Claim 28
Independent Claim
62 words
A method for the treatment of neoplastic disease selected from the group consisting of anal, breast, cervical, colorectal, head, lung, melanoma, and neck cancer, comprising administering to an animal suffering from or suspected of suffering from said disease a synergistically effective amount of (a) highly purified tumor necrosis factor; (b) highly purified type I interferon; and (c) highly purified type II interferon.
Claim 29
Dependent Claim
13 words
The method of claim 23 or 24, wherein said animal is a mammal.
Claim 30
Dependent Claim
10 words
The method of claim 25, wherein said mammal is human.
Claim 31
Dependent Claim
41 words
The method of claim 23 or 24, wherein the dose of tumor necrosis factor is between 0.1-1000 mg/kg body weight, and wherein the dose of type I and/or type II interferon is between 10 3 and 10 6 IU/kg body weight.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-12-13 | 1992-06-13 | 1992-12-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-12-13 | 1996-06-13 | 1996-12-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-12-13 | 2000-06-13 | 2000-12-13 | $7700.00 | Window Closed / Lapsed |